CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CORT$75.03+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $120,495 | $127,665 |
| Short-term marketable securities | 251,657 | 255,669 |
| Trade receivables, net of allowances | 59,786 | 53,976 |
| Inventory | 12,868 | 12,412 |
| Prepaid expenses and other current assets | 40,658 | 21,880 |
| Total current assets | 485,464 | 471,602 |
| Strategic inventory | 11,094 | 3,583 |
| Operating lease right-of-use asset | 4,583 | 5,324 |
| Property and equipment, net | 1,890 | 2,689 |
| Long-term marketable securities | 160,270 | 219,831 |
| Other assets | 5,153 | 6,610 |
| Deferred tax assets, net | 168,197 | 130,914 |
| Total assets | $836,651 | $840,553 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $40,444 | $15,376 |
| Accrued research and development expenses | 33,954 | 33,868 |
| Accrued and other liabilities | 90,603 | 90,700 |
| Short-term operating lease liability | 1,084 | 829 |
| Total current liabilities | 166,085 | 140,773 |
| Long-term operating lease liability | 5,023 | 6,107 |
| Long-term accrued government rebates | 2,562 | — |
| Long-term accrued income taxes payable | 15,176 | 14,084 |
| Total liabilities | 188,846 | 160,964 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, par value $0.001 per share, 280,000 shares authorized and 142,518 issued and 105,966 outstanding as of December 31, 2025 and 137,753 shares issued and 105,113 outstanding as of December 31, 2024 | 140 | 136 |
| Treasury stock; at cost; 36,552 shares of common stock as of December 31, 2025 and 32,640 shares of common stock as of December 31, 2024 | (966,586) | (696,173) |
| Additional paid-in capital | 968,600 | 832,108 |
| Accumulated other comprehensive income (loss) | 2,264 | (217) |
| Retained earnings | 643,387 | 543,735 |
| Total stockholders’ equity | 647,805 | 679,589 |
| Total liabilities and stockholders’ equity | $836,651 | $840,553 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.